Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

carfilzomib

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Proteasome inhibitor

Related drugs:

‹

bortezomib (90)

bortezomib (90)

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + carfilzomib Sensitive: A1 - Approval lenalidomide + carfilzomib Sensitive : A1	lenalidomide + carfilzomib Sensitive: A1 - Approval lenalidomide + carfilzomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	selinexor + carfilzomib Sensitive: A2 - Guideline selinexor + carfilzomib Sensitive : A2	selinexor + carfilzomib Sensitive: A2 - Guideline selinexor + carfilzomib Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib + pomalidomide Sensitive: A2 - Guideline carfilzomib + pomalidomide Sensitive : A2	carfilzomib + pomalidomide Sensitive: A2 - Guideline carfilzomib + pomalidomide Sensitive : A2
CD27 expression	Multiple Myeloma	CD27 expression	Multiple Myeloma	carfilzomib Sensitive: C3 – Early Trials carfilzomib Sensitive : C3	carfilzomib Sensitive: C3 – Early Trials carfilzomib Sensitive : C3
TMPRSS11E expression	Multiple Myeloma	TMPRSS11E expression	Multiple Myeloma	carfilzomib Sensitive: C3 – Early Trials carfilzomib Sensitive : C3	carfilzomib Sensitive: C3 – Early Trials carfilzomib Sensitive : C3
STRA6 expression	Multiple Myeloma	STRA6 expression	Multiple Myeloma	carfilzomib Sensitive: C3 – Early Trials carfilzomib Sensitive : C3	carfilzomib Sensitive: C3 – Early Trials carfilzomib Sensitive : C3
CLEC7A expression	Multiple Myeloma	CLEC7A expression	Multiple Myeloma	carfilzomib Sensitive: C3 – Early Trials carfilzomib Sensitive : C3	carfilzomib Sensitive: C3 – Early Trials carfilzomib Sensitive : C3
LPXN expression	Multiple Myeloma	LPXN expression	Multiple Myeloma	carfilzomib Sensitive: C3 – Early Trials carfilzomib Sensitive : C3	carfilzomib Sensitive: C3 – Early Trials carfilzomib Sensitive : C3
GPR176 expression	Multiple Myeloma	GPR176 expression	Multiple Myeloma	carfilzomib Sensitive: C3 – Early Trials carfilzomib Sensitive : C3	carfilzomib Sensitive: C3 – Early Trials carfilzomib Sensitive : C3
TK1 expression	Multiple Myeloma	TK1 expression	Multiple Myeloma	carfilzomib Sensitive: C3 – Early Trials carfilzomib Sensitive : C3	carfilzomib Sensitive: C3 – Early Trials carfilzomib Sensitive : C3
Chr t(11;14)(q13;q32)	Multiple Myeloma	Chr t(11;14)(q13;q32)	Multiple Myeloma	carfilzomib Resistant: C4 – Case Studies carfilzomib Resistant : C4	carfilzomib Resistant: C4 – Case Studies carfilzomib Resistant : C4
ABCB1 overexpression	Multiple Myeloma	ABCB1 overexpression	Multiple Myeloma	carfilzomib Resistant: D – Preclinical carfilzomib Resistant : D	carfilzomib Resistant: D – Preclinical carfilzomib Resistant : D
FASN-L	Acute Myelogenous Leukemia	FASN-L	Acute Myelogenous Leukemia	carfilzomib Sensitive: D – Preclinical carfilzomib Sensitive : D	carfilzomib Sensitive: D – Preclinical carfilzomib Sensitive : D
TOP2A overexpression	Multiple Myeloma	TOP2A overexpression	Multiple Myeloma	carfilzomib Resistant: D – Preclinical carfilzomib Resistant : D	carfilzomib Resistant: D – Preclinical carfilzomib Resistant : D
MUC20 underexpression	Mantle Cell Lymphoma	MUC20 underexpression	Mantle Cell Lymphoma	carfilzomib Resistant: D – Preclinical carfilzomib Resistant : D	carfilzomib Resistant: D – Preclinical carfilzomib Resistant : D
MYCN amplification	Rhabdomyosarcoma	MYCN amplification	Rhabdomyosarcoma	carfilzomib + VIP152 Sensitive: D – Preclinical carfilzomib + VIP152 Sensitive : D	carfilzomib + VIP152 Sensitive: D – Preclinical carfilzomib + VIP152 Sensitive : D
PAX5-JAK2 fusion	B Acute Lymphoblastic Leukemia	PAX5-JAK2 fusion	B Acute Lymphoblastic Leukemia	carfilzomib Sensitive: D – Preclinical carfilzomib Sensitive : D	carfilzomib Sensitive: D – Preclinical carfilzomib Sensitive : D